The changing lifestyle and diet are also contributing to the same
Tirzepatide has shown more weight loss in studies, but both are effective
GLP-1 Receptor Agonist Market Key Segments Drug : Semaglutide Exenatide Lixisenatide Liraglutide Dulaglutide Others Route of Administration : Oral Parenteral Indication : Diabetes Obesity Others Distribution Channel : Hospital Pharmacies Retail Pharmacies Online Pharmacies Region : North America USA Canada Mexico Europe Germany UK France Italy Spain Nordic Countries BENELUX Rest of Europe Asia Pacific China Japan South Korea India Australia Rest of Asia Pacific Latin America Brazil Argentina Rest of Latin America Middle East and Africa Kingdom of Saudi Arabia United Arab Emirates South Africa Rest of Middle East and Africa Other Regions Oceania Central Asia Other Markets - Frequently Asked Questions - How large is the demand for GLP-1 Receptor Agonists in the global market in 2026

GH reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), CardioVascular Research Initiative, European Union and the Klinkerpad fonds, institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company
For information on recommended timing of when to stop GLP1-RAs prior to pregnancy please see Glucagon-like peptide-1 receptor agonists during pregnancy and lactation
They are governed by state boards and by USP (sterile compounding) and USP (non-sterile compounding) standards